The Patent Finder

Terms ending in 2029

Eagle Pharmaceuticals, Inc.

Every in-force patent on Eagle Pharmaceuticals, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,801,892Fulvestrant Formulations
In force
 · High confidence
Eagle Pharmaceuticals, Inc.In forceHigh confidence
US 10,363,259Fulvestrant Formulations
In force
 · High confidence
Eagle Pharmaceuticals, Inc.In forceHigh confidence
US 7,803,762Ready-To-Use Bivalirudin Compositions
In force
 · Medium confidence
Sandoz Inc.In forceMedium confidence
US 7,713,928Ready-To-Use Bivalirudin Compositions
In force
 · Medium confidence
Sandoz Inc.In forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Eagle Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited